Vijay Kedia buys 9 lakh shares of SME stock Mahamaya Lifesciences in a Rs 12.5 crore block deal

Ace investors Vijay Kedia on Tuesday bought nearly 9 lakh shares of SME stock Mahamaya Lifesciences in a block deal. The shares were purchased at a price of Rs 140 each, taking the transaction value to Rs 12.48 crore.Kedia bought the shares through his investment company Kedia Securities Private Ltd at a discount of 2.8% to Monday’s closing price of Rs 144.05 per share.

Shares of Mahamaya Lifesciences, listed on November 18, 2025, hit their all-time high of Rs 161.70 on the BSE today.The shares also witnessed another block deal wherein Almondz Global Securities Limited sold 1.51 lakh shares at a price of Rs 143.64 per share.

Mahamaya Lifesciences is a manufacturer and exporter of pesticide formulations and crop protection products listed on the BSE SME platform.

The stock was trading at a mediocre quotation of Rs 116 per share against the issue price of Rs 114. But the stock has widened its lead since it made its market debut. It is now up 42% from its IPO price.

Also read: Ola Electric bulk deal: Promoter Bhavish Aggarwal sells 2.6 crore shares worth Rs 92 croreThe Rs 70.44 crore IPO consisted of a fresh issue worth Rs 64.28 crore and an offer for sale of Rs 6.16 crore.

The IPO was subscribed a total of 1.63 times, led by strong NII participation of 3.63 times, while the retail category ended at 1.02 times – just above full subscription. QIBs offer 1.19 times, reflecting a measured institutional stance. The high minimum investment size of Rs 2,73,600 for retail investors also meant limited participation from small applicants.

Mahamaya Lifesciences produces pesticide formulations, technical grade molecules and branded agricultural products. It supplies bulk products to domestic agrochemical companies and several multinationals.

The company also has a global footprint, with product registrations and sales in Egypt, Ethiopia, Jordan, the UAE and Turkey, among others. The product portfolio includes key formulations such as acetamiprid, emamectin benzoate, imidacloprid, paraquat dichloride and multi-brand plant health products.

The company posted strong growth in FY25, with revenue rising 64% to Rs 267.17 crore, while PAT grew 148% to Rs 12.94 crore. EBITDA rose to Rs 24.64 crore, and net assets almost doubled to Rs 49.42 crore.

Proceeds from the IPO will be used for equipment purchases, setting up a new engineering plant, warehouse construction, working capital needs and general corporate purposes.

Also read: Usha Martin block deal: Promoter entity sells stake worth Rs 99 crore. Morgan Stanley among buyers

(Disclaimer: The recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of The Economic Times.)